Scarica l'app Stockscreener
19.88
1.73%
-0.35
Dopo l'orario di chiusura:
19.87
-0.010
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Monday - MarketBeat
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High - MSN
Arrowhead Pharmaceuticals director sells shares valued at $20,139 By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals director sells shares valued at $20,139 - MSN
Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Sells 959 Shares of Stock - MarketBeat
HC Wainwright Has Bearish Outlook for ARWR FY2026 Earnings - MarketBeat
What is HC Wainwright’s Estimate for ARWR FY2026 Earnings? - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
Arrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthrough - MSN
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.4%Time to Sell? - MarketBeat
Leerink Partnrs Has Negative Estimate for ARWR Q3 Earnings - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 6%Here's Why - MarketBeat
Leerink Partnrs Issues Negative Estimate for ARWR Earnings - MarketBeat
(ARWR) Technical Data - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Cantor Fitzgerald Forecasts ARWR FY2025 Earnings - Defense World
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 - Yahoo Finance
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - The Bakersfield Californian
Equities Analysts Set Expectations for ARWR FY2025 Earnings - MarketBeat
FDA accepts Arrowhead's NDA for plozasiran - MSN
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment - MarketWatch
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Contrasting Janone (NASDAQ:ALTS) & Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals director sells shares totaling $121,555 ate«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.33 - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2%Should You Buy? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Sells $578,426.88 in Stock - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 Shares - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares - MarketBeat
Arrowhead Pharmaceuticals COO sells shares worth $736,058 By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock - Investing.com
Arrowhead Pharmaceuticals COO sells shares worth $736,058 - Investing.com
Arrowhead Pharmaceuticals CFO Kenneth Myszkowski sells $893,095 in stock By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $219,456 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CEO sells $219,456 in stock - Investing.com India
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $219,456.00 in Stock - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.5%Should You Sell? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by JPMorgan Chase & Co. - MarketBeat
B. Riley Has Strong Forecast for ARWR FY2025 Earnings - MarketBeat
(ARWR) Investment Analysis - Stock Traders Daily
Principal Financial Group Inc. Sells 133,772 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Principal Financial Group Inc. Lowers Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Franklin Resources Inc. - Defense World
Adeoye Y. Olukotun Sells 2,850 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock - MarketBeat
Insider Sell: Adeoye Olukotun Sells Shares of Arrowhead Pharmaceuticals Inc - GuruFocus.com
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):